Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Curti

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Journal for Immunotherapy of Cancer|February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Cancer|January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.
Immunity|August 2, 2015
Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent ImmunityGail D Sckisel, Myriam N Bouchlaka, Arta M Monjazeb, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Journal for Immunotherapy of Cancer|April 10, 2021
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitorBrendan D Curti, Yoshinobu Koguchi, Rom S Leidner, et al.
Molecular Therapy Oncolytics|February 22, 2021
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cellsTamson V Moore, Gina M Scurti, Matthew DeJong, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patientsB D Curti, A C Ochoa, W J Urba, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 27, 2022
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609Laurie E McLouth, Yue Zheng, Stephanie Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Scott S Tykodi, Gregory A Daniels, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Journal for Immunotherapy of Cancer|February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Cancer|January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.
Immunity|August 2, 2015
Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent ImmunityGail D Sckisel, Myriam N Bouchlaka, Arta M Monjazeb, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Journal for Immunotherapy of Cancer|April 10, 2021
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitorBrendan D Curti, Yoshinobu Koguchi, Rom S Leidner, et al.
Molecular Therapy Oncolytics|February 22, 2021
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cellsTamson V Moore, Gina M Scurti, Matthew DeJong, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patientsB D Curti, A C Ochoa, W J Urba, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 27, 2022
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609Laurie E McLouth, Yue Zheng, Stephanie Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Scott S Tykodi, Gregory A Daniels, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Pageof 13